Marshall Wace, LLP Compass Pathways PLC Transaction History

Marshall Wace, LLP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	N/A	40,809 Added 18.15%	265,613 $2.27 Million
Q3 2023 Nov 14, 2023	BUY	N/A	224,804 New	224,804 $1.92 Million
Q1 2022 May 16, 2022	SELL	$11.13 - $23.04 $396,806 - $821,422	-35,652 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$21.81 - $48.96 $446,712 - $1 Million	20,482 Added 135.02%	35,652 $788,000
Q3 2021 Nov 15, 2021	SELL	$29.03 - $38.62 $276,742 - $368,164	-9,533 Reduced 38.59%	15,170 $453,000
Q2 2021 Aug 13, 2021	BUY	$32.29 - $39.68 $797,659 - $980,215	24,703 New	24,703 $942,000

152

33.6M

536K

582K

Ticker CMPS
Exchange NASDAQ
Sector Healthcare
Industry Medical Care Facilities
Shares Outstandng 42,522,400
Market Cap $363M
Description
COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that has completed Phase IIb clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder. Th...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.